Literature DB >> 31103415

Knee-related quality of life, functional results and osteoarthritis at a minimum of 20 years' follow-up after anterior cruciate ligament reconstruction.

Matias Costa-Paz1, Ignacio Garcia-Mansilla2, Sebastian Marciano3, Miguel Angel Ayerza2, D Luis Muscolo2.   

Abstract

BACKGROUND: Few studies in the literature show results with more than 20 years of follow-up after anterior cruciate ligament reconstruction (ACLR). The main purpose of this retrospective study was to describe knee-specific quality of life, functional results and prevalence of osteoarthritis (OA) of the knee in patients with ACLR using bone-patellar tendon-bone (BPTB) autograft with ultra-long-term follow-up.
METHODS: Prospective analyzed data included demographics, meniscus status, radiographic OA, KT-1000 arthrometer measurements and physical examinations. KOOS, Lysholm and IKDC subjective surveys were conducted. Multivariate and univariate logistic models were used to determine the effect of potential predictors of OA and symptomatic knees.
RESULTS: Seventy-two knees were included at a median follow-up of 22 (IQR 21-25) years postoperatively. Radiographic scores were normal in 15%, nearly normal in 57%, abnormal in 18% and severely abnormal in 10%. Multivariate analysis showed that the predictive factor for the presence of OA in the long-term was an associated meniscal lesion; patients with meniscal lesions were 3.9 times as likely to develop OA in comparison with those without meniscal injury. The subjective scores were progressively and significantly lower as the level of OA was greater.
CONCLUSION: At a median of 22 years of follow-up, this study shows that patellar tendon autograft ACL reconstruction provides good clinical outcomes, with clinically objective knee stability and a 28% prevalence of OA. Additionally, we identified that meniscal injury at time of surgery was an independent predictor of OA. LEVEL OF EVIDENCE: Level IV; case series.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACL reconstruction; Knee function; Long-term outcome; Osteoarthritis

Mesh:

Year:  2019        PMID: 31103415     DOI: 10.1016/j.knee.2019.04.010

Source DB:  PubMed          Journal:  Knee        ISSN: 0968-0160            Impact factor:   2.199


  6 in total

1.  Platelet-rich plasma pretreatment protects anterior cruciate ligament fibroblasts correlated with PI3K-Akt-mTOR pathway under hypoxia condition.

Authors:  Yanwei Cao; Yue Li; Sai Chuen Fu; Jiewei Shen; Hui Zhang; Chunyan Jiang; Patrick Shu-Hang Yung
Journal:  J Orthop Translat       Date:  2022-03-10       Impact factor: 4.889

2.  Comparison of hamstring and quadriceps strength after anatomical versus non-anatomical anterior cruciate ligament reconstruction: a retrospective cohort study.

Authors:  Hai Jiang; Lei Zhang; Rui-Ying Zhang; Qiu-Jian Zheng; Meng-Yuan Li
Journal:  BMC Musculoskelet Disord       Date:  2021-05-18       Impact factor: 2.362

3.  Mucormycosis osteomyelitis after anterior cruciate ligament reconstruction: treatment and outcomes of 21 reported cases.

Authors:  Matias Costa-Paz; D Luis Muscolo; Miguel A Ayerza; Marisa Sanchez; Juan Astoul Bonorino; Carlos Yacuzzi; Lisandro Carbo
Journal:  Bone Jt Open       Date:  2021-01-03

Review 4.  Clinical Outcomes and Osteoarthritis at Very Long-term Follow-up After ACL Reconstruction: A Systematic Review and Meta-analysis.

Authors:  Alberto Grassi; Nicola Pizza; Belal Bashar Hamdan Al-Zu'bi; Giacomo Dal Fabbro; Gian Andrea Lucidi; Stefano Zaffagnini
Journal:  Orthop J Sports Med       Date:  2022-01-07

5.  Revision anterior cruciate ligament reconstruction: Return to sports at a minimum 5-year follow-up.

Authors:  Ezequiel Ortiz; Juan Pablo Zicaro; Ignacio Garcia Mansilla; Carlos Yacuzzi; Matias Costa-Paz
Journal:  World J Orthop       Date:  2022-09-18

6.  The subjective knee value is a valid single-item survey to assess knee function in common knee disorders.

Authors:  Fabian Plachel; Tobias Jung; Benjamin Bartek; Katja Rüttershoff; Carsten Perka; Clemens Gwinner
Journal:  Arch Orthop Trauma Surg       Date:  2021-02-01       Impact factor: 2.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.